Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients

Table 2 Proposed scoring systems for hepatocellular carcinoma patients undergoing transarterial chemoembolization

Ref.	Variables considered	Aim
Lladó et al[15]	AFP (> 400 UI/L), tumor size (> 50%) and CP score	Treatment selection
Kadalayil et al[16]	Albumin < 3.6 g/L, bilirubin > 17 μmol/L, AFP > 400 ng/mL and dominant tumor size > 7 cm	Treatment selection
Sieghart et al[17]	Increase of AST by > 25% and of CP score from baseline, tumor response	Treatment repetition
Adhoute et al[18]	BCLC, AFP (> 200 ng/mL), increase in CP score by ≥ 2 from baseline and tumor response	Treatment repetition
Pinato et al[19]	Normalization of CRP and serum albumin after TACE	Treatment repetition
Hucke et al[20]	Albumin level, tumour burden (reference: up-to-7 criteria) and CRP(≥ 1 mg/dL)	Treatment selection
Xu et al[21]	PVT, tumor number, tumor capsule, AFP, AST and ICR	Treatment selection
Sciarra et al[22]	CD34 and VEGF staining1	Treatment selection

¹Assessed in tumor biopsy. AFP: Alpha-fetoprotein; CP: Child-Pugh; AST: Aspartate transaminase; BCLC: Barcelona Clinic Liver Cancer; CRP: C-reactive protein; TACE: Transarterial chemoembolization; PVT: Portal vein thrombosis; ICR: Indocyanin retention test; VEGF: Vascular endothelial growth factor.